Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
(R)-3-Amino-N-((R)-4-oxo-1-phenyl-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-2-yl)-4-(2,4,5-trifluorophenyl)butanamide is an impurity of sitagliptin (S491000), which is a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has recently been approved for the therapy of type II diabetes.